CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
Atorvastatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03830164
NCT03830164Phase 2Completed
CompareCT.gov

Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction

M.D. Anderson Cancer Center·interventional·Posted Feb 5, 2019·Updated Oct 17, 2023

In Brief

A Phase 2 clinical trial evaluating Atorvastatin, Pentoxifylline, and 1 other intervention for Male Erectile Disorder and 3 related conditions. Completed, enrolled 14 participants across 1 site.

Detailed Summary

This phase II trial studies how well pentoxifylline, atorvastatin, and vitamin E (PAVE) work in treating patients with erectile dysfunction after radiation therapy for prostate cancer. Atorvastatin may reduce high cholesterol. Pentoxifylline and vitamin E may enhance blood flow. Giving PAVE may work better in treating prostate cancer patients with post-radiation therapy erectile dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Erectile Disorder, Prostate Adenocarcinoma, Erectile Dysfunction, CTCAE, Impotence
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 5, 2019
Enrollment StartNov 20, 2019
Primary CompletionNov 2, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.4 years ago

Interventions

Atorvastatindrug

Given PO

Pentoxifyllinedrug

Given PO

Vitamin E Compounddietary

Given PO